The Role of FLI1 in mRNA Splicing and rRNA Processing of Diffuse Large B Cell Lymphoma (DLBCL)

DLBCL is the commonest lymphoma, accounting for 30-40% of the cases, and a clinically aggressive lymphoma. A large portion of DLBCL patients can nowadays be cured with chemotherapeutic regimens, such as R-CHOP. However, approximately 30-40% of patients will present a refractory disease or will experience a relapse, indicating the need of better understanding the disorder for further therapeutic improvements. Our group has functionally characterized an 11q24.3 region that is recurrently gained in DLBCL determining an upregulation of the transcriptional factor FLI1 that occurs in up to 25% of patients (Bonetti, Testoni et al.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Giulio Sartori, Sara Napoli, Luciano Cascione, Valdemar Priebe, Andrea Rinaldi, Francesco Bertoni Source Type: research